N/A
Completed N=21
Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)
Legionnaires' Disease · Legionella Pneumophila Infections
Source: ClinicalTrials.gov NCT01784770 ↗
Enrolled (actual)
21
Serious AEs
4.8%
Results posted
Nov 2017
Primary outcomePrimary: Number of Participants With Treatment-Related Adverse Events — 2; 0 Participants
Summary
To collect retrospectively the efficacy and safety information of azithromycin IV on patients with Legionnaires' disease related to their appropriate use in daily practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment-Related Adverse Events |
2; 0 | — |
| SECONDARY Clinical Effectiveness Rate in Participants |
95.2 | — |
Eligibility Criteria
Inclusion Criteria
- All patients who are prescribed Azithromycin (Zithromac) IV for Legionnaires' disease.
Exclusion Criteria
- Patients who have been prescribed Zithromac or Zithromac SR.
Data sourced from ClinicalTrials.gov (NCT01784770). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.